TransMedics (TMDX)
Market Price (10/5/2026): $81.1 | Market Cap: $2.8 BilSector: Health Care | Industry: Health Care Equipment
TransMedics (TMDX)
Market Price (10/5/2026): $81.1Market Cap: $2.8 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.5% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 22%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, Biotechnology & Genomics, and Precision Medicine. Themes include Remote Patient Monitoring, Show more. | Weak multi-year price returns2Y Excs Rtn is -84%, 3Y Excs Rtn is -40% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.68 | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 29x Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 23% Key risksTMDX key risks include [1] a class-action lawsuit alleging fraud and historical FDA scrutiny of its OCS device, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.5% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 22%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, Biotechnology & Genomics, and Precision Medicine. Themes include Remote Patient Monitoring, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -84%, 3Y Excs Rtn is -40% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.68 |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 29x |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 23% |
| Key risksTMDX key risks include [1] a class-action lawsuit alleging fraud and historical FDA scrutiny of its OCS device, Show more. |
Qualitative Assessment
AI Analysis | Feedback
TransMedics (TMDX) stock has gained about 20% since 6/30/2026 because of the following key factors:
1. Strong Q2 2026 Revenue Performance and Raised Full-Year Guidance. TransMedics reported Q2 2026 revenue of $189.95 million, a 20.7% year-over-year increase, surpassing analysts' expectations of $184 million. Despite an earnings per share (EPS) miss of $0.06 against a consensus of $0.50, the company subsequently raised the lower end of its full-year 2026 revenue guidance to a range of $737 million to $757 million, indicating a projected growth of 22% to 25% over the prior year.
2. Increased Utilization of Organ Care System (OCS) and Expansion of Logistics Services. The substantial revenue growth in fiscal Q2 2026 was primarily driven by the increased adoption and utilization of TransMedics' Organ Care System (OCS), particularly for heart and liver transplants through the National OCS Program (NOP). This core business expansion, coupled with additional revenue generated from the company's logistics services, demonstrated successful operational execution and market penetration.
Show more
TransMedics (TMDX) stock has gained about 20% since 6/30/2026 because of the following key factors:
1. Strong Q2 2026 Revenue Performance and Raised Full-Year Guidance. TransMedics reported Q2 2026 revenue of $189.95 million, a 20.7% year-over-year increase, surpassing analysts' expectations of $184 million. Despite an earnings per share (EPS) miss of $0.06 against a consensus of $0.50, the company subsequently raised the lower end of its full-year 2026 revenue guidance to a range of $737 million to $757 million, indicating a projected growth of 22% to 25% over the prior year.
2. Increased Utilization of Organ Care System (OCS) and Expansion of Logistics Services. The substantial revenue growth in fiscal Q2 2026 was primarily driven by the increased adoption and utilization of TransMedics' Organ Care System (OCS), particularly for heart and liver transplants through the National OCS Program (NOP). This core business expansion, coupled with additional revenue generated from the company's logistics services, demonstrated successful operational execution and market penetration.
3. Positive Analyst Sentiment and Upgraded Price Targets. Analyst coverage reflected continued confidence in TransMedics, with a consensus "Buy" rating and an average 12-month price target ranging from $94.22 to $97.30. This implied an upside potential of approximately 13.49% to 14.08% from the stock's price in late September 2026, with some analysts, such as Piper Sandler, raising their price targets to $100 in September 2026.
4. Strategic International Expansion Plans to Broaden Market Reach. TransMedics has outlined strategic plans, including the potential replication of its successful U.S. National OCS Program (NOP) model in Europe, which represents approximately 45% of global transplant volumes. This international expansion is anticipated to nearly double the company's total addressable market and significantly increase its top-line revenue potential, providing a strong long-term growth outlook.
Show less
Stock Movement Drivers
Fundamental Drivers
The 20.1% change in TMDX stock from 6/30/2026 to 10/4/2026 was primarily driven by a 36.9% change in the company's P/E Multiple.| (LTM values as of) | 6302026 | 10042026 | Change |
|---|---|---|---|
| Stock Price ($) | 66.42 | 79.80 | 20.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 636 | 668 | 5.1% |
| Net Income Margin (%) | 27.0% | 22.7% | -16.1% |
| P/E Multiple | 13.3 | 18.2 | 36.9% |
| Shares Outstanding (Mil) | 34 | 35 | -0.6% |
| Cumulative Contribution | 20.1% |
Market Drivers
6/30/2026 to 10/4/2026| Return | Correlation | |
|---|---|---|
| TMDX | 20.1% | |
| Market (SPY) | 3.1% | 16.3% |
| Sector (XLV) | 4.7% | 38.9% |
Fundamental Drivers
The -19.7% change in TMDX stock from 3/31/2026 to 10/4/2026 was primarily driven by a -27.8% change in the company's Net Income Margin (%).| (LTM values as of) | 3312026 | 10042026 | Change |
|---|---|---|---|
| Stock Price ($) | 99.41 | 79.80 | -19.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 605 | 668 | 10.4% |
| Net Income Margin (%) | 31.4% | 22.7% | -27.8% |
| P/E Multiple | 17.9 | 18.2 | 1.7% |
| Shares Outstanding (Mil) | 34 | 35 | -1.0% |
| Cumulative Contribution | -19.7% |
Market Drivers
3/31/2026 to 10/4/2026| Return | Correlation | |
|---|---|---|
| TMDX | -19.7% | |
| Market (SPY) | 18.6% | 10.5% |
| Sector (XLV) | 13.8% | 14.7% |
Fundamental Drivers
The -28.9% change in TMDX stock from 9/30/2025 to 10/4/2026 was primarily driven by a -65.7% change in the company's P/E Multiple.| (LTM values as of) | 9302025 | 10042026 | Change |
|---|---|---|---|
| Stock Price ($) | 112.20 | 79.80 | -28.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 531 | 668 | 25.8% |
| Net Income Margin (%) | 13.5% | 22.7% | 68.2% |
| P/E Multiple | 53.1 | 18.2 | -65.7% |
| Shares Outstanding (Mil) | 34 | 35 | -1.9% |
| Cumulative Contribution | -28.9% |
Market Drivers
9/30/2025 to 10/4/2026| Return | Correlation | |
|---|---|---|
| TMDX | -28.9% | |
| Market (SPY) | 16.5% | 26.1% |
| Sector (XLV) | 20.9% | 20.0% |
Fundamental Drivers
The 45.7% change in TMDX stock from 9/30/2023 to 10/4/2026 was primarily driven by a 342.5% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 9302023 | 10042026 | Change |
|---|---|---|---|
| Stock Price ($) | 54.75 | 79.80 | 45.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 151 | 668 | 342.5% |
| P/S Multiple | 11.8 | 4.1 | -65.0% |
| Shares Outstanding (Mil) | 33 | 35 | -5.9% |
| Cumulative Contribution | 45.7% |
Market Drivers
9/30/2023 to 10/4/2026| Return | Correlation | |
|---|---|---|
| TMDX | 45.7% | |
| Market (SPY) | 86.2% | 28.3% |
| Sector (XLV) | 35.2% | 20.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| TMDX Return | -4% | 222% | 28% | -21% | 95% | -31% | 319% |
| Peers Return | -2% | -32% | 1% | 22% | 12% | 48% | 36% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 104% |
Monthly Win Rates [3] | |||||||
| TMDX Win Rate | 50% | 67% | 58% | 50% | 58% | 56% | |
| Peers Win Rate | 48% | 43% | 53% | 47% | 50% | 56% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| TMDX Max Drawdown | -60% | -38% | -62% | -66% | -28% | -58% | |
| Peers Max Drawdown | -49% | -60% | -59% | -41% | -39% | -35% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CDNA, BLFS, INSP, IRTC, PEN. See TMDX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/2/2026 (YTD)
How Low Can It Go
| Event | TMDX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -19.0% | -18.8% |
| % Gain to Breakeven | 23.4% | 23.1% |
| Time to Breakeven | 29 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -59.6% | -9.5% |
| % Gain to Breakeven | 147.5% | 10.5% |
| Time to Breakeven | 162 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -38.2% | -24.5% |
| % Gain to Breakeven | 61.8% | 32.4% |
| Time to Breakeven | 22 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -47.7% | -33.7% |
| % Gain to Breakeven | 91.1% | 50.9% |
| Time to Breakeven | 309 days | 140 days |
In The Past
TransMedics's stock fell -19.0% during the 2025 US Tariff Shock. Such a loss loss requires a 23.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | TMDX | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -59.6% | -9.5% |
| % Gain to Breakeven | 147.5% | 10.5% |
| Time to Breakeven | 162 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -38.2% | -24.5% |
| % Gain to Breakeven | 61.8% | 32.4% |
| Time to Breakeven | 22 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -47.7% | -33.7% |
| % Gain to Breakeven | 91.1% | 50.9% |
| Time to Breakeven | 309 days | 140 days |
In The Past
TransMedics's stock fell -19.0% during the 2025 US Tariff Shock. Such a loss loss requires a 23.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About TransMedics (TMDX)
TransMedics Group, Inc. (TMDX) is a commercial-stage medical technology company revolutionizing organ transplant therapy for patients suffering from end-stage organ failure. The company's core innovation is its proprietary Organ Care System (OCS), a portable platform designed to preserve, optimize, and monitor donor organs outside of the human body.
The Organ Care System utilizes customized technology to replicate near-physiologic conditions for organs prior to transplantation. TransMedics offers specialized OCS products for various organs, including OCS LUNG for the preservation of standard criteria donor lungs, OCS Heart for extracorporeal perfusion and preservation of donor hearts, and OCS Liver for the preservation of donor livers. These systems aim to enhance the viability and availability of donor organs.
TransMedics serves the global organ transplantation market, with its primary customers being transplant centers and hospitals in the United States and internationally. By improving the quality and accessibility of donor organs, the company ultimately benefits patients awaiting critical, life-saving transplants for lungs, hearts, and livers.
AI Analysis | Feedback
Here are 1-3 brief analogies for TransMedics:
- It's like GE HealthCare for donor organs, providing advanced, life-sustaining systems specifically for organs outside the body.
- Think of it as the Intuitive Surgical of organ transplantation, developing high-tech systems that transform how organs are preserved and utilized.
AI Analysis | Feedback
- Organ Care System (OCS): A portable organ perfusion, optimization, and monitoring system that replicates near-physiologic conditions for donor organs outside the human body.
- OCS LUNG: A component of the OCS specifically designed for the preservation of standard criteria donor lungs for double-lung transplantation.
- OCS Heart: A technology within the OCS used for extracorporeal perfusion and preservation of donor hearts.
- OCS Liver: A part of the OCS utilized for the preservation of donor livers.
AI Analysis | Feedback
TransMedics (TMDX) sells specialized medical technology, the Organ Care System (OCS), which is used in the complex process of organ transplantation. Therefore, its customers are not individuals but rather medical institutions.
The major category of customers that TransMedics serves is:
- Hospitals and Organ Transplant Centers: These are medical institutions, often large academic medical centers or specialized hospitals, that operate organ transplant programs for heart, lung, and liver recipients. They acquire TransMedics' OCS devices to improve the preservation, assessment, and utilization of donor organs, thereby aiming to expand the donor pool and enhance the success rates of transplantation procedures for end-stage organ failure patients.
AI Analysis | Feedback
AI Analysis | Feedback
Waleed Hassanein, M.D. TransMedics Founder, President and CEO
Dr. Waleed Hassanein founded TransMedics in 1998 with the aim of revolutionizing organ transplant therapy. His pioneering clinical research led to the development of a new field of living organ preservation for transplantation. He earned his M.D. from Georgetown University School of Medicine and completed a cardiac surgery research fellowship at the West Roxbury VA Medical Center and Brigham and Women's Hospital. In 1998, his research on ex-vivo heart perfusion for transplantation was recognized by the American Association for Thoracic Surgery. Dr. Hassanein has been recognized as a top Global Thinker in Healthcare and received the Tribeca Disruptive Innovator Award in 2018. He has served as a director of the company since August 1998.
Gerardo Hernandez Omana Chief Financial Officer and Treasurer
Gerardo Hernandez Omana was appointed Chief Financial Officer and Treasurer of TransMedics, effective December 2, 2024. He brings over 25 years of experience in finance across the healthcare and consumer packaged goods sectors. Before joining TransMedics, he served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals. Prior to that, he spent nearly a decade at Shire, where he led corporate FP&A and was instrumental in the integration efforts following Shire's $62 billion acquisition by Takeda. Mr. Hernandez began his career at Unilever. He holds a Bachelor of Science degree in Finance from the University of Wisconsin–La Crosse and an MBA in Strategy & Economics from Fundação Getulio Vargas, São Paulo.
Tamer Khayal, M.D. Chief Commercial Officer
Dr. Tamer Khayal joined TransMedics in 2001 and has since taken on increasing responsibilities, culminating in his appointment as Chief Commercial Officer in January 2018. From 2007 to 2018, he served as Chief Medical Officer, overseeing global initiatives for clinical evidence, reimbursement, and integration programs to support the approval and adoption of the Organ Care System (OCS) technology. Before joining TransMedics, Dr. Khayal was the Director of Medical Affairs for Zentiva Middle East, a pharmaceutical company. He received his M.D. degree from Cairo University School of Medicine.
Anil Ranganath Senior Vice President, General Counsel and Corporate Secretary
Nicholas Corcoran Senior Vice President of Supply Chain and Operations
AI Analysis | Feedback
Here are the key risks to TransMedics (TMDX) business:
- Regulatory and Legal Scrutiny: TransMedics faces significant risks due to ongoing legal actions and allegations of fraudulent practices. A class-action lawsuit has been filed, accusing the company of using kickbacks, engaging in fraudulent overbilling, employing coercive tactics to boost business, and concealing safety issues. There are also allegations of steering rejected organs to certain users and inadequate training of technicians managing organs on their OCS devices. These accusations expose TransMedics to heightened regulatory risk, potential legal liabilities, and reputational damage.
- Competition and Market Dynamics: The company operates in a competitive environment with other players developing organ preservation technologies, such as XVIVO Perfusion, OrganOx, and Paragonix Technologies. While TransMedics currently holds a strong market position, particularly in warm perfusion organ transplants in the United States, there is a risk of market saturation and slowing growth as the U.S. market matures. The emergence of alternative organ preservation protocols, such as Normothermic Regional Perfusion (NRP), could also limit the total addressable market for TransMedics' Organ Care System (OCS). Furthermore, international expansion may be challenging due to differing reimbursement models and regulatory hurdles, and increased competition in specific organ markets (e.g., liver transplants) could pressure market share and pricing.
- Operational and Supply Chain Challenges: TransMedics faces operational risks related to scaling its manufacturing and sterilization capabilities to meet increasing demand for its products. The company's reliance on single-source suppliers for key components also poses a vulnerability. Additionally, its National OCS Program (NOP) involves a complex logistics infrastructure, including an owned aviation fleet, which introduces risks such as potential disruptions in aviation services, fluctuating fuel costs, maintenance issues, and the company's relatively limited experience in operating aircraft.
AI Analysis | Feedback
Increased competition in the ex-vivo organ perfusion market, particularly from companies like XVIVO Perfusion launching competing systems for various organs, directly challenging TransMedics' market share and leadership.
AI Analysis | Feedback
TransMedics (TMDX) offers its Organ Care System (OCS) for the preservation and assessment of donor organs. The addressable markets for its main products are as follows:
-
OCS Liver: The global Organ Care System market for liver is estimated to reach approximately $40.5 million by the end of 2026. In North America, the OCS market size for liver is projected to reach $17.4 million by 2026.
-
OCS Lung: The global Organ Care System market for lung is forecasted to generate approximately $5.6 million in revenue by 2026. For North America, the OCS lung market size is expected to grow to approximately $1.2 million by 2026.
-
OCS Heart: Specific addressable market size for the OCS Heart product was not explicitly quantified in the search results. However, TransMedics is actively working to expand the addressable heart transplant market through its OCS Heart technology and clinical trials.
AI Analysis | Feedback
TransMedics Group, Inc. (TMDX) is expected to drive future revenue growth over the next two to three years through several key initiatives and expansions:
- Increased Utilization of Organ Care System (OCS) in the U.S. The company anticipates continued revenue growth from the expanded adoption and utilization of its Organ Care System (OCS) for existing indications, particularly in liver and heart transplants, within its National OCS Program (NOP) in the United States. TransMedics reported a significant increase in U.S. OCS cases, reaching 5,139 in 2025, up 38% year-over-year.
- Expansion of Transplant Logistics Infrastructure. Revenue growth is also expected from the ongoing expansion and heightened utilization of TransMedics' proprietary transplant logistics services, including its aviation fleet. The company continues to invest in and leverage its robust logistics capabilities to support the National OCS Program, enhancing its ability to cover NOP missions requiring air transport.
- International Market Expansion. TransMedics is focused on expanding its NOP model into international markets. Active launches are underway in European markets, with Italy specifically highlighted for the first half of 2026. This international expansion is projected to significantly increase the company's total addressable market and contribute to future revenue growth.
- Introduction of New OCS Programs and Indications. The company is investing in and advancing its clinical pipeline to develop and launch new OCS programs and expand existing indications. This includes progress with programs such as OCS Kidney, for which the company aims to have the platform ready for FDA trials by early 2027, as well as the OCS ENHANCE Heart and DENOVO Lung programs. These new offerings are expected to broaden the clinical adoption of OCS technology and serve as significant revenue catalysts.
AI Analysis | Feedback
Share Issuance
- TransMedics completed an underwritten public offering of 3,250,000 shares of its common stock at $40.00 per share in August 2022, generating gross proceeds of approximately $130 million.
Capital Expenditures
- TransMedics reported capital expenditures of approximately $151.85 million in fiscal year 2023 and $129.74 million in fiscal year 2024.
- For the trailing twelve months ending September 30, 2025, capital expenditures were approximately $57.34 million.
- The primary focus of capital expenditures has been on ongoing upgrades to expand manufacturing, enhancing infrastructure for long-term scalability, and the expansion of its owned and operated aircraft fleet for organ transport, which reached 22 aircraft as of December 31, 2025. Investments also support research, clinical programs, and commercial infrastructure.
Peer Outperformance in Health Care Equipment
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 12.8% | 43.2% | 91.3% | CAH 414% · MCK 366% · COR 175% |
| Health Care Services | 20 | 18.8% | 36.3% | 9.1% | HIMS 295% · RDNT 144% · DGX 81% |
| Managed Health Care | 8 | 25.4% | -8.6% | 4.2% | OSCR 92% · HQY 38% · ELV 11% |
| Health Care Facilities | 24 | -2.1% | 5.0% | -3.6% | THC 291% · NHC 272% · ENSG 131% |
| Health Care Equipment ← | 50 | -8.9% | -0.2% | -16.2% | POCI 11050% · UFPT 374% · GKOS 253% |
| Pharmaceuticals | 62 | -7.4% | -2.8% | -30.9% | INDV 1117% · ETON 1046% · LQDA 953% |
| Health Care Supplies | 12 | 21.5% | -4.9% | -37.5% | LNTH 296% · HAE 52% · MMSI 19% |
| Life Sciences Tools & Services | 109 | -5.7% | -11.3% | -66.7% | SNWV 1867% · NTRA 269% · MEDP 210% |
| Health Care Technology | 21 | -35.8% | -55.3% | -79.1% | SPOK 79% · HSTM 10% · VEEV -2% |
| Biotechnology | 362 | -18.3% | -24.6% | -79.3% | CELZ 1252% · ELVN 1139% · DNTH 1108% |
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 74.39 |
| Mkt Cap | 3.1 |
| Rev LTM | 747 |
| Op Inc LTM | 29 |
| FCF LTM | 82 |
| FCF 3Y Avg | 13 |
| CFO LTM | 120 |
| CFO 3Y Avg | 64 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 25.5% |
| Rev Chg 3Y Avg | 21.2% |
| Rev Chg Q | 20.4% |
| QoQ Delta Rev Chg LTM | 4.9% |
| Op Inc Chg LTM | 60.6% |
| Op Inc Chg 3Y Avg | 63.0% |
| Op Mgn LTM | 4.5% |
| Op Mgn 3Y Avg | -3.0% |
| QoQ Delta Op Mgn LTM | 1.6% |
| CFO/Rev LTM | 18.0% |
| CFO/Rev 3Y Avg | 11.8% |
| FCF/Rev LTM | 12.4% |
| FCF/Rev 3Y Avg | 3.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 3.1 |
| P/S | 6.0 |
| P/Op Inc | 35.3 |
| P/EBIT | 46.6 |
| P/E | 24.8 |
| P/CFO | 39.8 |
| Total Yield | 3.2% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 0.5% |
| D/E | 0.0 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 2.5% |
| 3M Rtn | 24.3% |
| 6M Rtn | 11.3% |
| 12M Rtn | 7.4% |
| 3Y Rtn | 49.2% |
| 1M Excs Rtn | 0.7% |
| 3M Excs Rtn | 20.7% |
| 6M Excs Rtn | -6.0% |
| 12M Excs Rtn | -3.4% |
| 3Y Excs Rtn | -44.7% |
Comparison Analyses
Price Behavior
| Market Price | $79.80 | |
| Market Cap ($ Bil) | 2.8 | |
| First Trading Date | 05/02/2019 | |
| Distance from 52W High | -47.0% | |
| 50 Days | 200 Days | |
| DMA Price | $85.25 | $100.07 |
| DMA Trend | down | up |
| Distance from DMA | -6.4% | -20.3% |
| 3M | 1YR | |
| Volatility | 45.4% | 57.4% |
| Downside Capture | 67.26 | 133.23 |
| Upside Capture | 132.32 | 67.11 |
| Correlation (SPY) | 16.3% | 25.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.86 | 1.34 | 0.69 | 0.50 | 1.15 | 1.28 |
| Up Beta | -0.96 | 0.39 | -0.27 | -0.26 | 0.95 | 1.38 |
| Down Beta | 2.12 | 2.79 | -0.09 | 1.18 | 1.59 | 1.07 |
| Up Capture | 68% | 173% | 173% | 23% | 68% | 186% |
| Bmk +ve Days | 6 | 16 | 27 | 66 | 132 | 424 |
| Stock +ve Days | 9 | 18 | 31 | 61 | 122 | 363 |
| Down Capture | 147% | 112% | 46% | 100% | 121% | 107% |
| Bmk -ve Days | 16 | 26 | 37 | 60 | 120 | 328 |
| Stock -ve Days | 13 | 23 | 32 | 64 | 129 | 385 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TMDX | |
|---|---|---|---|---|
| TMDX | -30.6% | 57.1% | -0.42 | - |
| Sector ETF (XLV) | 17.4% | 15.7% | 0.82 | 19.6% |
| Equity (SPY) | 16.2% | 13.0% | 0.88 | 26.0% |
| Gold (GLD) | 6.8% | 29.6% | 0.22 | 10.6% |
| Commodities (DBC) | 44.9% | 20.8% | 1.67 | -4.5% |
| Real Estate (VNQ) | 1.5% | 13.6% | -0.15 | 9.6% |
| Bitcoin (BTCUSD) | -28.9% | 44.3% | -0.64 | 12.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TMDX | |
|---|---|---|---|---|
| TMDX | 21.0% | 71.6% | 0.56 | - |
| Sector ETF (XLV) | 6.4% | 15.2% | 0.23 | 27.4% |
| Equity (SPY) | 13.1% | 17.2% | 0.58 | 37.6% |
| Gold (GLD) | 18.4% | 18.9% | 0.79 | 3.6% |
| Commodities (DBC) | 10.3% | 19.6% | 0.41 | 2.0% |
| Real Estate (VNQ) | 0.7% | 18.8% | -0.07 | 26.5% |
| Bitcoin (BTCUSD) | 14.6% | 52.2% | 0.45 | 18.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TMDX | |
|---|---|---|---|---|
| TMDX | 14.4% | 71.0% | 0.56 | - |
| Sector ETF (XLV) | 10.4% | 16.7% | 0.50 | 28.0% |
| Equity (SPY) | 15.3% | 17.9% | 0.72 | 35.7% |
| Gold (GLD) | 11.5% | 16.4% | 0.57 | 3.3% |
| Commodities (DBC) | 8.2% | 18.1% | 0.37 | 8.2% |
| Real Estate (VNQ) | 4.2% | 20.7% | 0.16 | 28.0% |
| Bitcoin (BTCUSD) | 64.1% | 66.2% | 1.04 | 16.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 9/10/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/4/2026 | -5.3% | 10.7% | 4.4% |
| 5/5/2026 | -23.2% | -32.7% | -24.8% |
| 2/27/2026 | 7.9% | 4.1% | -26.4% |
| 10/29/2025 | 1.1% | -7.3% | 12.0% |
| 7/30/2025 | 10.5% | 10.3% | 8.4% |
| 5/8/2025 | 19.6% | 30.7% | 49.6% |
| 2/27/2025 | 5.8% | -9.5% | -4.9% |
| 10/28/2024 | -29.9% | -32.7% | -36.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 15 | 15 | 15 |
| # Negative | 9 | 9 | 9 |
| Median Positive | 14.1% | 11.9% | 21.0% |
| Median Negative | -9.3% | -16.8% | -21.0% |
| Max Positive | 51.2% | 53.1% | 96.6% |
| Max Negative | -29.9% | -32.7% | -36.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/4/2026 | -5.3% | 10.7% | 4.4% |
| 5/5/2026 | -23.2% | -32.7% | -24.8% |
| 2/27/2026 | 7.9% | 4.1% | -26.4% |
| 10/29/2025 | 1.1% | -7.3% | 12.0% |
| 7/30/2025 | 10.5% | 10.3% | 8.4% |
| 5/8/2025 | 19.6% | 30.7% | 49.6% |
| 2/27/2025 | 5.8% | -9.5% | -4.9% |
| 10/28/2024 | -29.9% | -32.7% | -36.1% |
| 7/31/2024 | 6.5% | 2.5% | 17.1% |
| 4/30/2024 | 24.9% | 35.2% | 44.9% |
| 2/26/2024 | 14.1% | 11.9% | -4.2% |
| 11/6/2023 | 51.2% | 48.4% | 84.0% |
| 8/3/2023 | -8.3% | -26.3% | -21.0% |
| 5/1/2023 | -5.2% | -8.9% | -6.7% |
| 2/22/2023 | 20.5% | 26.0% | 14.4% |
| 11/3/2022 | 24.0% | 24.6% | 37.2% |
| 8/1/2022 | -10.3% | 10.8% | 23.7% |
| 5/3/2022 | 40.3% | 15.1% | 30.3% |
| 2/23/2022 | 30.0% | 53.1% | 96.6% |
| 11/9/2021 | -9.3% | -20.4% | -26.8% |
| 8/5/2021 | 8.5% | 7.4% | 16.0% |
| 5/4/2021 | -11.1% | -16.8% | -9.8% |
| 3/2/2021 | -5.6% | -14.0% | 4.5% |
| 11/4/2020 | 4.9% | 11.5% | 21.0% |
| SUMMARY STATS | |||
| # Positive | 15 | 15 | 15 |
| # Negative | 9 | 9 | 9 |
| Median Positive | 14.1% | 11.9% | 21.0% |
| Median Negative | -9.3% | -16.8% | -21.0% |
| Max Positive | 51.2% | 53.1% | 96.6% |
| Max Negative | -29.9% | -32.7% | -36.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/04/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 10/29/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 10/29/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/27/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/04/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 10/29/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 10/29/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/27/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/03/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 03/01/2022 | 10-K |
| 09/30/2021 | 11/09/2021 | 10-Q |
| 06/30/2021 | 08/06/2021 | 10-Q |
| 03/31/2021 | 05/07/2021 | 10-Q |
| 12/31/2020 | 03/11/2021 | 10-K |
| 09/30/2020 | 11/06/2020 | 10-Q |
| 06/30/2020 | 08/10/2020 | 10-Q |
| 03/31/2020 | 05/06/2020 | 10-Q |
| 12/31/2019 | 03/17/2020 | 10-K |
| 09/30/2019 | 11/08/2019 | 10-Q |
Recent Forward Guidance
Updated 10/4/2026Latest: Q2 2026 Earnings Reported 8/4/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 737.00 Mil | 747.00 Mil | 757.00 Mil | Raised | Guidance: 742.00 Mil for 2026 | ||
| 2026 Revenue Growth | Reported | 22.0% | 23.5% | 25.0% | 1.0% | Raised | Guidance: 22.5% for 2026 | |
Prior: Q3 2025 Earnings Reported 10/29/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | Reported | 595.00 Mil | 600.00 Mil | 605.00 Mil | Raised | Guidance: 595.00 Mil for 2025 | ||
| 2025 Revenue Growth | Reported | 36.0% | ||||||
Insider Activity
Updated 9/14/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Weill, David | Direct | Buy | 9142026 | 81.63 | 1,336 | 109,058 | 1,338,079 | Form | |
| 2 | Gunderson, Thomas J | Direct | Sell | 6172026 | 75.06 | 9,624 | 722,377 | 1,249,149 | Form | |
| 3 | Lovell, Stephanie | Direct | Sell | 3062026 | 149.62 | 1,193 | 178,497 | 428,811 | Form | |
| 4 | Weill, David | Direct | Sell | 3062026 | 146.82 | 3,571 | 524,294 | 1,781,514 | Form | |
| 5 | Hernandez, Gerardo | Chief Financial Officer | Direct | Sell | 3042026 | 147.21 | 7,236 | 1,065,212 | 2,162,368 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Weill, David | Direct | Buy | 9142026 | 81.63 | 1,336 | 109,058 | 1,338,079 | Form | |
| 2 | Gunderson, Thomas J | Direct | Sell | 6172026 | 75.06 | 9,624 | 722,377 | 1,249,149 | Form | |
| 3 | Lovell, Stephanie | Direct | Sell | 3062026 | 149.62 | 1,193 | 178,497 | 428,811 | Form | |
| 4 | Weill, David | Direct | Sell | 3062026 | 146.82 | 3,571 | 524,294 | 1,781,514 | Form | |
| 5 | Hernandez, Gerardo | Chief Financial Officer | Direct | Sell | 3042026 | 147.21 | 7,236 | 1,065,212 | 2,162,368 | Form |
| 6 | Hernandez, Gerardo | Chief Financial Officer | Direct | Sell | 3042026 | 139.12 | 375 | 52,170 | 2,043,534 | Form |
| 7 | Ranganath, Anil P | See remarks | Direct | Sell | 3042026 | 139.12 | 864 | 120,200 | 1,821,220 | Form |
| 8 | Corcoran, Nicholas | See remarks | Direct | Sell | 3042026 | 139.12 | 2,966 | 412,630 | 4,150,089 | Form |
| 9 | Hernandez, Gerardo | Chief Financial Officer | Direct | Sell | 12052025 | 139.62 | 920 | 128,450 | 2,103,236 | Form |
| 10 | Weill, David | Direct | Sell | 12052025 | 138.64 | 5,000 | 693,200 | 1,682,258 | Form | |
| 11 | Ranganath, Anil P | See remarks | Direct | Sell | 11262025 | 145.22 | 3,000 | 435,660 | 2,026,545 | Form |
| 12 | Hassanein, Waleed H | President & CEO | the Waleed H. Hassanein Revocable Trust | Buy | 11182025 | 114.00 | 8,775 | 1,000,350 | 56,431,026 | Form |
| 13 | Basile, Edward M | Direct | Sell | 10312025 | 130.45 | 4,142 | 540,324 | 373,870 | Form |
Investor Activity (13F)
Updated Oct 5, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.